Q2 2012 Earnings Call
July 26, 2012 8:30 am ET
Christopher A. Viehbacher - Chief Executive Officer, Director and Member of Strategy Committee
Hanspeter Spek - President of Global Operations
Olivier Charmeil - Senior Vice President of Sanofi Pasteur - Vaccines Division
Jerome Contamine - Chief Financial Officer and Executive Vice President
Richard Vosser - JP Morgan Chase & Co, Research Division
Michael Leuchten - Barclays Capital, Research Division
Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division
Philippe Lanone - Natixis Bleichroeder LLC, Research Division
Graham Parry - BofA Merrill Lynch, Research Division
Jo Walton - Crédit Suisse AG, Research Division
Mark Clark - Deutsche Bank AG, Research Division
Peter Verdult - Morgan Stanley, Research Division
Vincent Meunier - Exane BNP Paribas, Research Division
Welcome to the Sanofi 2012 Second Quarter Results Conference Call. I now hand over to Mr. Sébastien Martel and to Mr. Christoph Viehbacher. Sir, please go ahead. .
Thank you. Hi, everyone, and welcome to our second quarter conference call. As always I must advise you that the information presented today in the call contains forward-looking statements that involve known and unknown risks and uncertainties that may cause actual results to differ materially. So I'd like to please ask you refer to our Form 20-F on file with the SEC and also our Document de Référence for a description of these risk factors.
So with me today on the call are Chris Viehbacher, our CEO; Hanspeter Spek, our President of Global Operations; Olivier Charmeil, Senior VP for Vaccines; and Jerome Contamine, our CFO.